IMTX250117C17500
- 0.08
- 0.000.00%
Immatics Newsroom
Clear Street Launches Healthcare & Biotechnology Equity Research
Bristol Myers Squibb Terminates Agreements With Immatics Due To Ongoing Portfolio Prioritization Efforts Within BMS For Allogeneic Programs; Collaboration With BMS Under The 2019 Multi-Target TCR-T Strategic Collaboration Agreement Remains Ongoing
Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16
Mizuho Securities Sticks to Its Buy Rating for Immatics (IMTX)
Immatics N.V. Reports Strong Q3 2024 Progress and Financials
Goldman Sachs Initiates Immatics(IMTX.US) With Buy Rating, Announces Target Price $13.5
Immatics Moved to Buy From Not Rated at Goldman Sachs
Earnings Update: Immatics N.V. (NASDAQ:IMTX) Just Reported And Analysts Are Boosting Their Estimates
Immatics Analyst Ratings
BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $15
Jefferies Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $20
BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Cuts Target Price to $15
Leerink Partners Maintains Immatics(IMTX.US) With Buy Rating, Announces Target Price $18
Immatics Price Target Lowered to $18 From $19 at Leerink
What Makes Immatics (IMTX) a New Buy Stock
Express News | Immatics NV : Piper Sandler Cuts Target Price to $18 From $19
Immatics Sees Revenue Surge Despite R&D Expenses
Immatics Sees Cash Runway Into 2H27
Immatics N.V. Reports Promising Clinical Data for TCR Bispecific Molecules and Advances Four Cancer Therapy Candidates
Immatics GAAP EPS of -€0.11, Revenue of €50.56M